Ravandi, F., Sayar, S., Ritchie, E., Strickland, S., Craig, M., Recher, C., … Feldman, E. (2012). VALOR, AN ADAPTIVE DESIGN, PIVOTAL PHASE 3 TRIAL OF VOSAROXIN OR PLACEBO IN COMBINATION WITH CYTARABINE IN FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. In HAEMATOLOGICA (Vol. 97, pp. 504–504). FERRATA STORTI FOUNDATION.

Ravandi, F., S. Sayar, E. Ritchie, S. Strickland, M. Craig, C. Recher, D. Selleslag, et al. “VALOR, AN ADAPTIVE DESIGN, PIVOTAL PHASE 3 TRIAL OF VOSAROXIN OR PLACEBO IN COMBINATION WITH CYTARABINE IN FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.” In HAEMATOLOGICA, 97:504–504. FERRATA STORTI FOUNDATION, 2012.

Ravandi F, Sayar S, Ritchie E, Strickland S, Craig M, Recher C, et al. VALOR, AN ADAPTIVE DESIGN, PIVOTAL PHASE 3 TRIAL OF VOSAROXIN OR PLACEBO IN COMBINATION WITH CYTARABINE IN FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2012. p. 504–504.

Ravandi, F., et al. “VALOR, AN ADAPTIVE DESIGN, PIVOTAL PHASE 3 TRIAL OF VOSAROXIN OR PLACEBO IN COMBINATION WITH CYTARABINE IN FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.” HAEMATOLOGICA, vol. 97, FERRATA STORTI FOUNDATION, 2012, pp. 504–504.

Ravandi F, Sayar S, Ritchie E, Strickland S, Craig M, Recher C, Selleslag D, Maertens J, Lancet J, Havelange V, Hertzberg M, Acton G, Mehta C, Silva E, Fox J, Stuart R, Erba H, Vey N, Schiller G, Feldman E. VALOR, AN ADAPTIVE DESIGN, PIVOTAL PHASE 3 TRIAL OF VOSAROXIN OR PLACEBO IN COMBINATION WITH CYTARABINE IN FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2012. p. 504–504.